Study may explain why immunotherapy not effective for some patients with metastatic melanoma and kidney cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint blockade therapy, according to a study at MD Anderson Cancer Center. Study results will be presented April 2 at the AACR Annual Meeting 2019 in Atlanta.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login